SCHEMBL4414675

SCHEMBL4414675

CC(=O)Oc1cc(N)n[nH]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 2/20 0.33
CYP19A1 P11511 1/20 0.33
ACHE P22303 2/20 0.33
GAA P10253 2/20 0.32
ALDH1A1 P00352 3/20 0.32
KMT2A Q03164 2/20 0.32
MITF O75030 1/20 0.32
TP53 P04637 1/20 0.32
LMNA P02545 2/20 0.32
CYP3A4 P08684 1/20 0.32
TNFSF11 O14788 1/20 0.32
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
KDM4E B2RXH2 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
MAPK1 P28482 1/20 0.31
MKNK1 Q9BUB5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27848505 0.98 DYRK1A (0.34) DYRK1ASMN1; SMN2HSD17B10CYP19A1ACHE
SCHEMBL27865531 0.78 CYP3A4 (0.40) SMN1; SMN2HSD17B10ACHEGAAALDH1A1
SCHEMBL27974432 0.78 LMNA (0.36) HSD17B10ACHEGAAALDH1A1TP53
SCHEMBL4276128 0.78 DAO (0.34) ACHEGAAALDH1A1LMNACYP3A4
SCHEMBL27864491 0.77 MAPK1 (0.38) ACHELMNACYP3A4TNFSF11PDE3B
SCHEMBL27633318 0.74 HCAR2 (0.36) SMN1; SMN2HSD17B10ACHEGAAALDH1A1
SCHEMBL27683380 0.72 DYRK1A (0.34) DYRK1AACHEGAAALDH1A1PDE3B
Hydrochloric Acid SCHEMBL219321 0.71
SCHEMBL27906348 0.70 GAA (0.55) SMN1; SMN2GAAKMT2ATP53RAB9A
SCHEMBL27801324 0.70 HCAR2 (0.45) DYRK1ASMN1; SMN2HSD17B10GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102762571-A Heterocyclic compounds as janus kinase inhibitors BIOCRYST PHARM INC 2012-10-31 CN disclosed
CN-101443339-B Process for the preparation of pyrazolylaminoquinazoline derivatives comprising a phosphate group ASTRAZENECA AB 2012-07-04 CN disclosed
CN-101074227-B Phosphine acyloxy quinazoline derivatives and their medicine uses ASTRAZENECA AB 2010-09-29 CN disclosed
EP-1463506-B1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES ASTRAZENECA AB (SE) 2009-10-21 EP disclosed
CN-101448501-A Combination therapy for the treatment of cancer ASTRAZENECA AB (SE) 2009-06-03 CN disclosed
CN-101448823-A Maleate cocrystals of AZD1152 ASTRAZENECA AB (SE) 2009-06-03 CN disclosed
CN-100491372-C Substituted quinazoline derivatives as inhibitors of aurora kinase ASTRAZENECA AB (SE) 2009-05-27 CN disclosed
CN-101443339-A Process for the preparation of pyrazolylaminoquinazoline derivatives comprising a phosphate group ASTRAZENECA AB (SE) 2009-05-27 CN disclosed
CN-101115738-A Pyrazolylamino substituted quinazoles for the treatment of cancer ASTRAZENECA AB (SE) 2008-01-30 CN disclosed
CN-101074227-A Phosphine acyloxy quinazoline derivatives and their medicine using ASTRAZENECA AB (SE) 2007-11-21 CN disclosed
CN-100349906-C Phosphonoxyquinazoline derivatives and pharmaceutical use thereof ASTRAZENECA AB (SE) 2007-11-21 CN disclosed
CN-1764668-A Phosphonoxyquinazoline derivatives and pharmaceutical use thereof ASTRAZENECA AB (SE) 2006-04-26 CN disclosed
CN-1620296-A Substituted quinazoline derivatives as inhibitors of aurora kinases ASTRAZENECA AB (SE) 2005-05-25 CN disclosed
EP-1463506-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES Astrazeneca AB (SE) 2004-10-06 EP disclosed
WO-2003055491-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES ASTRAZENECA AB (SE) 2003-07-10 WO disclosed